Health In Tech Reports First Quarter 2026 Financial Results

Rhea-AI Summary

Health In Tech (Nasdaq:HIT) reported unaudited Q1 2026 revenue of $8.8 million, up 9.4% year over year. Platform placed plan value reached $82.0 million.

Adjusted EBITDA was $(1.3) million and net loss was $1.6 million or $(0.03) per diluted share.

Distribution partners grew 29.5% to 896. Contracted revenue for the remaining 2026 quarters totaled $22.9 million. Cash was $10.3 million and working capital $15.0 million.

The company reiterated 2026 revenue guidance of $45–$50 million, implying 35%–50% growth, and completed a March PIPE financing with about $7 million in gross proceeds.

AI-generated analysis. Not financial advice.

Positive

• Q1 2026 revenue $8.8M, up 9.4% year over year
• Distribution partners up 29.5% to 896 by March 31, 2026
• Contracted revenue remaining 2026 quarters totals $22.9M
• Cash balance $10.3M vs. $7.6M a year earlier
• Working capital $15.0M vs. $8.8M as of March 31, 2025
• Reiterated 2026 revenue guidance of $45M–$50M, 35%–50% growth
• Approximately $7M gross proceeds from March 2026 PIPE financing

Negative

• Adjusted EBITDA $(1.3)M vs. $1.2M in Q1 2025
• Net loss $1.6M vs. $0.5M net income in Q1 2025

Key Figures

Q1 2026 revenue: $8.8 million Revenue growth: 9.4% Adjusted EBITDA: $(1.3) million +5 more

8 metrics

Q1 2026 revenue $8.8 million Three months ended March 31, 2026; up from $8.0 million in Q1 2025

Revenue growth 9.4% Year-over-year increase in Q1 2026 revenue vs Q1 2025

Adjusted EBITDA $(1.3) million Q1 2026, versus $1.2 million in Q1 2025

Net result and EPS Net loss $1.6M, $(0.03) per share Q1 2026; vs net income $0.5M, $0.01 per share in Q1 2025

2026 revenue guidance $45–$50 million Reiterated full-year 2026 outlook; ~35%–50% YoY growth

Contracted 2026 revenue $22.9 million Contracted revenue for remaining three quarters of 2026 as of March 31, 2026

Cash balance $10.3 million Cash and cash equivalents as of March 31, 2026; up from $7.6 million a year earlier

Private placement proceeds $7.0 million Gross proceeds from March 2026 PIPE financing completed at $1.25 per share

Market Reality Check

Price: $1.5200 Vol: Volume 37,058 is below th...

low vol

$1.5200 Last Close

Volume Volume 37,058 is below the 20-day average of 109,068 (relative volume 0.34x). low

Technical Shares at $1.52 trade below the $2.01 200-day MA and remain 62.19% under the 52-week high, though still 173.82% above the 52-week low.

Peers on Argus

HIT was up 2.7% while key software/insurtech peers like DUOT, SSTI, EXFY, SVCO, ...

HIT was up 2.7% while key software/insurtech peers like DUOT, SSTI, EXFY, SVCO, and ASUR showed declines between about -0.58% and -3.38%, indicating a stock-specific move around these earnings.

Previous Earnings Reports

5 past events · Latest: Mar 25 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 25	Full-year 2025 earnings	Positive	-11.1%	Strong 2025 growth and initial 2026 revenue guidance of $45–$50M.
Nov 10	Q3 2025 earnings	Positive	-26.4%	Q3 2025 revenue and EBITDA growth with higher distribution partners and cash.
Jul 21	Q2 2025 earnings	Positive	+25.2%	Strong Q2 2025 revenue, adjusted EBITDA gains, and network expansion.
Apr 14	Q1 2025 earnings	Positive	+1.9%	Q1 2025 revenue and EBITDA growth with higher enrolled employees.
Mar 17	Full-year 2024 earnings	Negative	-18.3%	Mixed 2024 results with client and employee declines despite higher revenue.

Pattern Detected

Earnings releases have featured strong growth metrics but an average -5.71% price move, with several past updates selling off despite positive fundamentals.

Recent Company History

Over the past year, HIT’s earnings reports have highlighted rapid revenue growth and expanding distribution, with full-year 2024 revenue at $19.5M and 2025 revenue rising to $33.3M. Quarterly updates through 2025 repeatedly showed strong year-over-year gains and rising adjusted EBITDA, though market reactions were often negative, including moves of -18.25% and -26.37%. The current Q1 2026 release reiterates the $45–$50M 2026 revenue outlook, connecting to prior guidance while showing a shift from profitability to investment-led losses.

Historical Comparison

-5.7% avg move · Past earnings releases averaged a -5.71% move despite strong growth metrics, framing today’s Q1 2026...

earnings

-5.7%

Average Historical Move earnings

Past earnings releases averaged a -5.71% move despite strong growth metrics, framing today’s Q1 2026 update within a historically volatile earnings reaction pattern.

Earnings have progressed from mixed 2024 results to strong 2025 revenue and EBITDA growth, followed by 2026 guidance of $45–$50M and now Q1 2026 results that emphasize reinvestment and distribution expansion.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2026-04-24

An effective-date pending Form S-3 filed on 2026-04-24 registers 5,600,000 Class A shares for resale by PIPE investors. The filing states the company will receive no proceeds from these secondary sales, indicating potential selling liquidity for existing holders but no new primary capital.

Market Pulse Summary

This announcement highlights modest Q1 2026 revenue growth to $8.8 million but a pivot to a $1.6 mil...

Analysis

This announcement highlights modest Q1 2026 revenue growth to $8.8 million but a pivot to a $1.6 million net loss and $(1.3) million adjusted EBITDA as management invests for expansion. Reiterated 2026 revenue guidance of $45–$50 million and contracted revenue of $22.9 million underline visibility into near-term sales. Investors may track how added capital from the $7.0 million PIPE, growing distribution partners, and upcoming product rollouts translate into margin recovery versus continued spending.

Key Terms

adjusted EBITDA, non-GAAP financial measure, private investment in public equity financing

3 terms

adjusted EBITDA financial

"Adjusted EBITDA2 totaled $(1.3) million, compared to $1.2 million..."

Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.

non-GAAP financial measure financial

"Adjusted EBITDA is a non-GAAP financial measure. More information can be found..."

A non-GAAP financial measure is a way companies present their financial results that excludes certain expenses or income to show how they believe their core business is performing. It matters because it can give a clearer picture of how the company is really doing, but it can also be used to make results look better than they actually are.

private investment in public equity financing financial

"we successfully completed a private investment in public equity financing, which provided..."

A private investment in public equity financing (PIPE) is when a publicly traded company raises money by selling shares or rights that can turn into shares directly to a small group of private investors, rather than through a broad public offering. It matters to investors because it delivers quick capital that can help fund growth or shore up finances, but it also usually increases the number of shares outstanding, diluting existing shareholders’ ownership—similar to taking a fast, private loan in exchange for a piece of the company.

AI-generated analysis. Not financial advice.

Reiterates Guidance for 2026 Annual Revenue Ranging between $45 Million and $50 Million

STUART, Fla., May 13, 2026 /PRNewswire/ -- Health In Tech, Inc. (Nasdaq: HIT) ("Health In Tech" or "Company"), an AI-enabled InsurTech platform company, today announced its unaudited financial results for the three months ended March 31, 2026.

First Quarter 2026 Overview

• Revenue increased 9.4% to $8.8 million from $8.0 million in the first quarter of 2025.
• Platform placed plan value¹ totaled $82.0 million.
• Adjusted EBITDA² totaled $(1.3) million, compared to $1.2 million in the first quarter of 2025, and reflected higher sales and marketing expenses for initiatives designed to drive long-term revenue growth.
• Net loss equaled $1.6 million, or $(0.03) per diluted share, compared to net income of $0.5 million, or $0.01 per diluted share, in the first quarter of 2025.

As of March 31, 2026

• Distribution partners, including brokers, third-party administrators ("TPAs") and agencies, reached 896, up 29.5% from 692 distribution partners as of March 31, 2025.
• Contracted revenue³ for the remaining three quarters of 2026 equaled $22.9 million.
• Cash and cash equivalents totaled $10.3 million, compared to $7.6 million as of March 31, 2025.
• Working capital totaled $15.0 million, compared to $8.8 million as of March 31, 2025.   

2026 Full Year Revenue Guidance

Health In Tech today reiterated guidance for 2026 annual revenue ranging between $45 million and $50 million, representing year-over-year growth of approximately 35% to 50%.  As of March 31, 2026, the Company's contracted revenue for the remaining three quarters of 2026 totaled $22.9 million, which the Company believes provides useful visibility into 2026 full year revenue. Health In Tech's revenue outlook is based on management's current expectations and assumptions, including continued strong demand for the Company's AI-enabled underwriting marketplace across the self-funded health insurance segment and successful deployment of new features. Actual results may differ materially due to risks and uncertainties described in Health In Tech's filings with the SEC.

The Company expects continued growth driven by expanding engagement across its distribution network and the full deployment of new features launched in January 2026. Unlike the traditional insurance industry, where new product and service implementations typically require one to two years, Health In Tech's AI-driven platform enables new capabilities to be developed and deployed within approximately one to two quarters. This accelerated development cycle provides a meaningful competitive advantage, allowing the Company to respond quickly to broker and client demand, continuously enhance its marketplace offerings, and scale its technology platform more efficiently than traditional market participants.

CEO Commentary

Tim Johnson, Chief Executive Officer of Health In Tech, commented, "In the first quarter of 2026, we continued to execute on strategic priorities to scale our innovative AI-powered self-funded health insurance marketplace and drive revenue growth. In March, we successfully completed a private investment in public equity financing, which provided the Company with approximately $7 million in gross proceeds. We intend to allocate a portion of these proceeds to growth initiatives, including expanding our sales team, broadening our marketing activities, delivering new marketplace offerings, and enhancing the technology architecture and data analytics that underpin our disruptive platform. Through these measures we aim to increase the number of brokers, agencies, third party administrators, and carriers that utilize our efficient, cost-effective ecosystem."

Mr. Johnson continued, "We intend for 2026 to be a year of investing for growth and launching new solutions to further penetrate the vast U.S. self-funded health insurance market. Our recently rolled out suite of more than 100 pre-configured, customized stop-loss plans as well as our new three-year rate stabilization program are poised to deliver meaningful revenue beginning in the second half of the year. We also are developing a data-driven offering that integrates physiological and claims data to generate actionable insights. By layering in new capabilities such as these onto our platform, we better serve our ecosystem partners and business employer end-clients, while creating new revenue streams and operating leverage for Health In Tech."

End Notes

1. Platform placed plan value ("PPPV") represents the aggregate contractual value of self-funded health plans with stop-loss insurance (self-funded stop-loss plans) placed through the Company's platform, covering the duration of the plans' contractual terms. The contractual term is typically 12 months from the plan's effective date.  
2. Adjusted EBITDA is a non-GAAP financial measure. More information can be found in the "Non-GAAP Financial Information" section at the end of this press release.
3. Contracted revenue represents contractually committed revenue under active policies as of the measurement date that is expected to be recognized in future periods. Our policies are typically written for terms of 12 months, and revenue is recognized ratably over the life of the policy.

Conference Call Details

Health In Tech will host a conference call to discuss the financial results for the first quarter of 2026 on May 13, 2026, at 5:00 p.m. (ET). To participate in our live conference call and webcast, please dial 1-888-346-8982 or 1-412-902-4272 (for international participants).

A live audio webcast will be available via the Investor Relations page of Health In Tech's website at https://healthintech.com/. A replay of the webcast will be available for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

Non-GAAP Financial Information

This release presents Adjusted EBITDA, a non-GAAP financial metric, which is provided as a complement to the results provided in accordance with accounting principles generally accepted in the United States of America ("GAAP"). Management uses Adjusted EBITDA to provide investors with additional insight into operational performance and to facilitate comparison with other companies in the industry. Adjusted EBITDA should not be considered an alternative to net income, operating income, or other GAAP measures. A reconciliation of historical non-GAAP financial information to the most directly comparable GAAP financial measure is provided in the accompanying tables found at the end of this release.

Use of Forward‑Looking Statements

Certain statements in this press release are forward-looking statements for purposes of the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may include estimates or expectations about Health In Tech's possible or assumed operational results, financial condition, business strategies and plans, market opportunities, competitive position, industry environment, and potential growth opportunities. In some cases, forward-looking statements can be identified by terms such as "may," "will," "should," "design," "target," "aim," "hope," "expect," "could," "intend," "plan," "anticipate," "estimate," "believe," "continue," "predict," "project," "potential," "goal," or other words that convey the uncertainty of future events or outcomes. These statements relate to future events or to Health In Tech's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause Health In Tech's actual results, levels of activity, performance, or achievements to be different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond Health In Tech's control and which could, and likely will, affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects Health In Tech's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to Health In Tech's operations, results of operations, growth strategy and liquidity.

About Health In Tech 

Health In Tech, Inc. (Nasdaq: "HIT") is an AI-enabled InsurTech platform company, which offers a marketplace that improves processes in the health insurance industry through vertical integration, process simplification, and automation. By removing friction and complexities, we streamline the underwriting, sales and service process for insurance companies, licensed brokers, Managing General Underwriter ("MGUs") and third-party administrators ("TPAs"). Health In Tech's platform serves as a marketplace for brokers, TPAs, MGUs and carriers to access self-funded health insurance for employers, providing functions including customized self-funded health plans, bindable stop-loss quotes, AI-enabled underwriting, claims administration and reporting integration.

        

Health In Tech, Inc.
Consolidated Statements of Operations
（Unaudited）
		Three Months Ended March 31,
		2026		2025
Revenues
Revenues from underwriting modeling (ICE)		$1,468,814		$2,351,984
Revenues from fees (SMR)		7,302,832		5,663,000
Total revenues		8,771,646		8,014,984
Cost of revenues		4,262,247		2,659,585
Gross profit		4,509,399		5,355,399
Operating expenses
Sales and marketing expenses		2,291,601		1,090,255
General and administrative expenses		3,455,558		3,246,765
Research and development expenses		920,395		537,721
Total operating expenses		6,667,554		4,874,741
Other income:
Interest income		67,471		85,366
Other income		22,334		118,399
Total other income, net		89,805		203,765
Income (loss) before income taxes		$(2,068,350)		$684,423
Income tax benefit (expense)		480,069		(185,831)
Net income (loss)		$(1,588,281)		$498,592
Net income (loss) per share
Basic		$(0.03)		$0.01
Diluted		$(0.03)		$0.01
Weighted average common stocks outstanding
Basic		57,353,021		54,619,858
Diluted		57,353,021		56,996,936

 

Health In Tech, Inc. Consolidated Balance Sheets （Unaudited）
		March 31, 2026		December 31, 2025
Assets
Current assets
Cash and cash equivalents		$10,325,208		$7,669,754
Accounts receivable, net		3,737,647		756,288
Loans receivable, net		831,994		815,995
Other receivables, net		4,328,448		3,467,814
Deferred offering costs		-		170,977
Prepaid expenses and other current assets		2,864,557		3,280,148
Total current assets		22,087,854		16,160,976
Non-current assets
Software		6,708,561		6,530,894
Operating lease - right of use assets		122,328		139,940
Long-term prepaid expenses		47,464		258,151
Total non-current assets		6,878,353		6,928,985
Total assets		$28,966,207		$23,089,961
Liabilities and stockholders' equity
Current liabilities
Accounts payable and accrued expenses		6,968,261		$4,188,811
Operating lease liabilities - current		78,680		76,195
Other current liabilities		-		891,598
Total current liabilities		7,046,941		5,156,604
Non-current liabilities
Deferred tax liabilities		273,203		757,675
Operating lease liabilities - non-current		42,915		63,617
Total non-current liabilities		316,118		821,292
Total liabilities		7,363,059		5,977,896
Stockholders' equity
Common stock, $0.001 par value; Class A Common stock      150,000,000 shares authorized 53,858,276 and      46,006,000 shares issued and outstanding as of March      31, 2026 and December 31, 2025, respectively		53,858		46,006
Common stock, $0.001 par value; Class B Common stock      50,000,000 shares authorized, 11,700,000 shares      issued and outstanding as of both March 31, 2026 and      December 31, 2025		11,700		11,700
Additional paid-in capital		17,905,633		11,834,121
Retained earnings		3,631,957		5,220,238
Total stockholders' equity		21,603,148		17,112,065
Total liabilities and stockholders' equity		$28,966,207		$23,089,961

 

Health In Tech, Inc.
Consolidated Statements of Cash Flows （Unaudited）
		Three Months Ended March 31,
		2026		2025
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)		$(1,588,281)		$498,592
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Amortization expense		403,467		135,983
Provision for refund liability		108,402		780,045
Deferred tax benefit		(484,472)		(34,473)
Interest income		(15,999)		(15,999)
Stock-based compensation expense		366,562		493,171
Changes in operating assets and liabilities:
Accounts receivable		(2,981,360)		(463,498)
Other receivables		(11,740)		(3,489,536)
Prepaid expenses and other assets		447,597		(1,017,751)
Operating lease right of use assets and liabilities, net		(605)		19
Accounts payable and accrued expenses		1,437,182		3,420,497
Income taxes payable		-		220,303
Other current liabilities		(1,000,000)		-
Net cash provided by (used in) operating activities		(3,319,247)		527,353
CASH FLOWS FROM INVESTING ACTIVITIES:
Development of software		(362,131)		(703,475)
Net cash used in investing activities		(362,131)		(703,475)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock in connection with private investment in public equity financing, net of placement agent fees and escrow agent fees		6,381,000		-
Payments of deferred offering costs		(44,168)		(98,089)
Net cash provided by (used in) financing activities		6,336,832		(98,089)
Increase (decrease) in cash and cash equivalents		2,655,454		(274,211)
Cash and cash equivalents, beginning of the period		7,669,754		7,849,248
Cash and cash equivalents, end of the period		10,325,208		7,575,037
Supplemental disclosures of cash flow information:
Cash paid for interest		$-		$-
Cash received from income tax refunds		$4,965		$-
Summary of noncash investing and financing activities:
Accrued deferred offering costs included in accounts      payable and accrued expenses		$237,734		$33,250
Accrued development of software included in accounts      payable and accrued expenses		$228,518		$256,140
Reclassification of deferred offering costs to additional paid-      in capital upon private investment in public equity      financing		$452,880		$-
Stock-based compensation capitalized for software      development		$8,837		$-

 

Health In Tech, Inc.
Reconciliation of GAAP Net Income (Loss) to Non-GAAP Financial Measure Adjusted EBITDA
					Three Months Ended March 31,
				2026							2025
Net income (loss)				(1,588,281)							498,592
Interest income				(67,471)							(85,366)
Amortization expense				403,467							135,983
Income tax expense (benefit)				(480,069)							185,831
Stock-based compensation expense, including employer payroll taxes related to stock-based awards				443,839							493,171
Total net adjustments				299,766							729,619
Adjusted EBITDA				(1,288,515)							1,228,211

 

Investor Contact:
Health In Tech Investor Relations
ir@healthintech.com

The Equity Group
Kalle Ahl, CFA          
T: (303) 953-9878     
kahl@theequitygroup.com

Devin Sullivan, Managing Director
dsullivan@theequitygroup.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/health-in-tech-reports-first-quarter-2026-financial-results-302771089.html

SOURCE Health In Tech, Inc.

FAQ

What were Health In Tech (HIT) Q1 2026 revenue and growth?

Health In Tech reported Q1 2026 revenue of $8.8 million, a 9.4% year-over-year increase. According to Health In Tech, this compares with $8.0 million in Q1 2025 and reflects growth in its AI-enabled self-funded health insurance marketplace.

What loss per share did Health In Tech (HIT) post in Q1 2026?

Health In Tech reported a Q1 2026 net loss of $1.6 million, or $(0.03) per diluted share. According to Health In Tech, this compares with net income of $0.5 million, or $0.01 per diluted share, in Q1 2025.

What 2026 revenue guidance did Health In Tech (HIT) reiterate on May 13, 2026?

Health In Tech reiterated 2026 annual revenue guidance of $45 million to $50 million. According to Health In Tech, this range implies approximately 35% to 50% year-over-year growth and reflects expected demand for its AI-enabled underwriting marketplace and new platform features.

How much contracted revenue does Health In Tech (HIT) have for the rest of 2026?

Health In Tech reported $22.9 million of contracted revenue for the remaining three quarters of 2026. According to Health In Tech, this represents contractually committed revenue under active policies that is expected to be recognized ratably over typical 12‑month policy terms.

How did Health In Tech (HIT) adjusted EBITDA change in Q1 2026?

Health In Tech reported Q1 2026 adjusted EBITDA of $(1.3) million, compared with $1.2 million in Q1 2025. According to Health In Tech, this reflects higher sales and marketing expenses tied to initiatives aimed at driving long-term revenue growth.

How many distribution partners did Health In Tech (HIT) have as of March 31, 2026?

Health In Tech reported 896 distribution partners as of March 31, 2026, including brokers, TPAs and agencies. According to Health In Tech, this represents a 29.5% increase from 692 partners as of March 31, 2025, supporting broader platform engagement.

What financing did Health In Tech (HIT) complete in March 2026?

Health In Tech completed a March 2026 private investment in public equity (PIPE) raising about $7 million in gross proceeds. According to Health In Tech, a portion is planned for growth initiatives, including sales expansion, marketing, new marketplace offerings and technology enhancements.